Mangalam Drugs: The Default Signal — Balance Sheet Under Pressure
Bank defaults of ₹15.57 crore, negative margins, and a stock down 64% from highs signal fundamental distress. What's happening to Mangalam's cash position?
₹27.99
Jul 15 close, −60% YTD
−64.1%
high ₹77.90 (Oct 2025)
+23.3%
low ₹22.70
MICRO-CAP
Limited liquidity & coverage
₹67.3 Cr
Loss ₹13.4 Cr, NPM −19.9%
₹15.57 Cr
BoB + BoM, 30+ days overdue
The distress cascade — defaults, losses, and the credit signal
Subsequent default on bank loans — ₹15.57 Cr overdue since October 2025
Mangalam Drugs filed a subsequent default intimation covering ₹606 lacs owed to Bank of Baroda (since Oct 20, 2025) and ₹951 lacs owed to Bank of Maharashtra (since Oct 17, 2025). Total overdue: ₹15.57 crore, exceeding 30 days. The company states it is 'arranging to pay the overdue amounts as soon as possible' — the standard placeholder language when cash position is strained.
Read:Bank defaults are the clearest signal of financial distress. A company that cannot service its creditors signals deep cash pressure — either operational collapse or a balance-sheet hole. When defaults cross ₹15 crore on a ₹67 crore quarterly-revenue business (23% of revenue), it raises the question: where is the cash? Covenant breaches and forced asset sales often follow.
BSE filing, Jul 15, 2026FY26 approval: ₹13.4 Cr loss in Q4, negative margins throughout
The board approved consolidated results for FY26 Q4 (ending Mar 31, 2026): revenue ₹67.3 Cr, net loss ₹13.4 Cr, operating margin −8.35%, net profit margin −19.92%. Both Q3 and Q4 were loss-making — Q3 revenue ₹58.5 Cr, loss ₹9.8 Cr, margin −16.69%. The audit report contains no modified opinions, but the numbers speak for themselves.
Read:A business losing nearly 20% of revenue in both recent quarters is not in a temporary rough patch. This indicates structural unprofitability — either demand collapse, unmanaged cost structure, or asset impairments. Combined with bank defaults, it suggests the company may lack the cash or earnings to service debt.
BSE filing, May 14, 2026Trading window closure for Q1 FY27 results
Mangalam Drugs announced closure of the trading window for designated persons from July 1, 2026, until 48 hours after Q1 FY27 results declaration. This is routine SEBI (Prohibition of Insider Trading) Regulations compliance and does not signal distress on its own.
Read:The timing is noteworthy: insiders are locked out just as the bank defaults became public and before Q1 results. Insiders may know whether the company is in active restructuring talks or whether defaults trigger covenants that could dilute existing shareholders.
BSE filing, Jun 25, 2026The sequence is clear: negative margins in Q3 and Q4 FY26 → cash position strained → bank defaults from October 2025 onwards → subsequent default intimations in May and July. The stock fell 64% from October highs to current lows. The market has priced in distress; the question now is whether the company restructures, sells assets, or faces insolvency proceedings.
From ₹77 to ₹28: a eight-month collapse
39.9
Neutral; oversold territory tested many times
27.99
−64% from high; near low
- vs 20-DMA (₹28.58)
- vs 50-DMA (₹29.18)
- vs 200-DMA (₹37.98)
Trend: bearish; all averages declining
The technical picture is uniformly negative. The stock has been in free fall since the October ATH, crossing below all major moving averages and testing support levels repeatedly. RSI at 39.9 sits in neutral territory but has been oversold many times — a sign of capitulation selling and lack of support. Volume is normal, not panic-driven, which suggests the move is grinding (not a shock spike) but relentless.
Back-to-back quarterly losses; cash position deteriorating
All figures consolidated, as reported on BSE XBRL. Both recent quarters unprofitable with deteriorating margins.
The financial picture is unambiguously distressed. Q3 and Q4 of FY26 both reported net losses, with margins worsening quarter-over-quarter. Operating margins turned negative in Q3 (−2.51%), worsened in Q4 (−8.35%), and net margins fell to −19.92% in Q4. This is not a margin compression story — it's a business losing money on revenue. The ₹15.57 crore in bank defaults against ₹67 crore quarterly revenue means roughly one-quarter of annual revenue is tied up in unpaid debt. If losses persist, covenant breaches and forced asset sales become likely.
₹30.55
Overhead; if broken, next target ₹37–38
₹27.99
₹27.00
Critical level; breach opens ₹22.70 (52w low)
The next 30–60 days are critical
Debt restructuring talks
BoB and BoM may initiate one-time settlement (OTS) negotiations or demand accelerated repayment. Any covenant-breach notices or asset-sale announcements would be material negative signals.
Q1 FY27 results
Due by mid-August. If Q1 is also loss-making, it confirms the business has not stabilized. Any improvement in margins or cash flow would be a required positive surprise.
Insider buying or promoter support
If promoters inject capital or insiders buy at these levels, it signals confidence in a turnaround. Absence of such support is a red flag.
Credit rating downgrade
ICRA, CRISIL, or CARE may downgrade Mangalam's rating on the defaults. A downgrade to 'D' (default) or suspension would lock the company out of fresh borrowing and trigger more covenant breaches.
₹27 support break
If the stock closes below ₹27 (30-day support), the next technical level is ₹22.70 (52w low). A break there opens the risk of a further 20–30% fall in the absence of material positive news.
Mangalam Drugs faces a classic distress scenario: unprofitable operations, material bank defaults, and a stock collapsed 64% from October highs. The ₹15.57 crore in overdue bank debt is the smoking gun — it signals that internal cash generation cannot cover the company's obligations. While 'arranging to pay' is the standard response, the real question is whether the company has a viable path to profitability or whether restructuring (asset sales, equity dilution, insolvency) is inevitable.
The data points to fundamental distress, not temporary headwinds. Until the company stabilizes margins, clears defaults, or announces a concrete turnaround plan, the risk-reward remains heavily weighted to the downside. Micro-cap status, limited liquidity, and minimal analyst coverage amplify volatility. Position sizing and risk management are essential for any exposure to this story.
Informational and educational content only. Not investment advice.